Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR.
Latest News
Share this

Author: Keystone Heart

Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ Cerebral Protection Device during TAVR

Keystone Heart today announced that its CE marked TriGuard™ Cerebral Protection Device has improved in-hospital safety outcomes and cognitive scores at discharge during Transcatheter Aortic Valve Replacement (TAVR). Based on changes in NIH Stroke Scale, patients protected with TriGuard had 10% absolute reduction in stroke (4.9%...

New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR

New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR. New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart’s TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when compared to historical...